Abstract: A method of generating an HIV-specific cytotoxic T-cell response in a host involves an initial administration of a T-helper molecule to the host to prime T-helper cells of the immune system of the host and a subsequent administration to the host of a mixture of the T-helper molecule and a T-cell inducing HIV-derived molecule to generate an HIV-specific T-cell response in the host.
Type:
Application
Filed:
April 7, 1998
Publication date:
September 6, 2001
Inventors:
CHARLES D. Y. SIA, PELE CHONG, MICHEL H. KLEIN
Abstract: The present invention relates to new variants of the human immunodeficiency virus (HIV) TAT protein which exhibit a transdominant phenotype, as well as to the DNA fragments encoding said variants, the expression cassettes permitting their expression by the recombinant route and the cells containing them. The transdominant variants of the TAT protein are especially useful for the prevention or treatment of HIV infections.
Abstract: A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.
Type:
Grant
Filed:
March 27, 1998
Date of Patent:
September 4, 2001
Assignee:
Institut Pasteur
Inventors:
Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
Abstract: Immunogenic compositions comprising soluble, non-cleavable, chimeric HIV-1 gp160 variants capable of eliciting human immunodeficiency virus type 1 (HIV-1) gp160-specific antibodies are provided. These HIV-1 gp160 variants comprise the following regions: i) a first region derived from the gp160 of a first strain of HIV-1; ii) a second region derived from the gp160 of a second strain of HIV-1 wherein said second region fails to contain functional major and minor proteolytic cleavage sites (amino acids 483-486 and 475-479, respectively) and functional major and minor hydrophobic domains (amino acids 487-516 and 659-680, respectively); and iii) an optional third region, derived from the gp160 of said second strain, located at the amino terminus of the recombinant envelope.
Abstract: The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.
Abstract: An antigenic peptide fragment from the p17 gag protein of HIV includes a portion from HGP-30 and a contiguous portion from HGP-35 such that the peptide fragment is capable of inducing a TH1 immune response when administered to a person suffering from AIDS or at risk for AIDS. The peptide has from about 25 to about 37 amino acids, such as, for example, the sequence
A T L Y S V 1 H Q R I D V K D T
SEQ ID NO.
Abstract: The claimed invention is directed toward in vitro methods for the detection of human immunodeficiency virus type 2 (HIV-2) antibodies employing polypeptide fragments of HIV-2 Gag.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
July 24, 2001
Assignee:
Institut Pasteur
Inventors:
Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
Abstract: The invention relates to an isolated immune complex comprising a protein and an antibody that binds with said protein, wherein the protein is selected from the group consisting of gp80 of HIV-2 and gp65 of SIV, wherein said gp80 is a glycoprotein having an apparent molecular weight of 80 kDa, as determined by SDS-PAGE, and further wherein said gp65 is a glycoprotein having an apparent molecular weight of 65 kDa as determined by SDS-PAGE. Also provided are an immunogenic composition comprising an amount of gp80 protein of human immunodeficiency virus type 2 (HIV-2) sufficient to induce an immune response and a pharmaceutically acceptible carrier, and a composition comprising at least one antigen selected from the group consisting of gp80 protein of HIV-2 and gp65SIV.
Type:
Grant
Filed:
December 27, 1994
Date of Patent:
July 17, 2001
Assignee:
Institute Pasteur
Inventors:
Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
Abstract: The present invention describes synthetic human monoclonal antibodies that immunoreact with and neutralize human immunodeficiency virus (HIV). The synthetic monoclonal antibodies of this invention exhibit enhanced binding affinity and neutralization ability to gp120. Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell lines for producing the monoclonal antibodies.
Type:
Grant
Filed:
February 20, 1996
Date of Patent:
July 17, 2001
Assignee:
The Scripps Research Institute
Inventors:
Carlos F. Barbas, Dennis R. Burton, Richard A. Lerner
Abstract: Synthetic peptide antigen analogues of native peptide antigens with partial or complete retro, inverso or retro-inverso modifications are provided. When administered as an immunogen to an immunocompetent host the synthetic peptide antigen analogues induce the production of antibodies which recognize the native peptide antigen. Uses of these analogues, vaccines and methods of preparing vaccines comprising these antigen analogues, and antibodies generated using these antigen analogues are also provided.
Type:
Grant
Filed:
August 12, 1997
Date of Patent:
July 17, 2001
Assignee:
Deakin Research Limited
Inventors:
Alfio Comis, Margaret Isabel Tyler, Peter Fischer
Abstract: This invention is directed toward soluble, non-cleavable, chimeric human immunodeficiency virus type 1 (HIV-1) gp160 variants, expression vectors encoding said variants, and methods of producing said variants. These HIV-1 gp160 variants comprise the following regions: I) a first region derived from the gp160 of a first strain of HIV-1; ii) a second region derived from the gp160 of a second strain of HIV-1 wherein said second region fails to contain functional major and minor proteolytic cleavage sites (amino acids 483-486 and 475-479, respectively) and functional major and minor hydrophobic domains (amino acids 487-516 and 659-680, respectively); and iii) an optional third region, derived from the gp160 of said second strain, located at the amino terminus of the recombinant envelope.
Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.
Type:
Grant
Filed:
December 31, 1997
Date of Patent:
July 17, 2001
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Inventors:
Marc Alizon, Pierre Sonigo, Cole Stewart, Oliver Danos, Simon Wain-Hobson
Abstract: A method of preventing a respiratory infection by administering DNA which encodes IFN is provided. Also provided is a therapy for the prevention of a respiratory infection containing DNA which encodes IFN.
Type:
Application
Filed:
February 23, 1999
Publication date:
July 5, 2001
Inventors:
SHYAM S. MOHAPATRA, HIROTO MATSUSE, ARUNA K. BEHERA, MUKESH KUMAR
Abstract: Three new HIV-1 isolates HIV-1 D747(ECACC V92082718), HIV-1 D757(ECACC V92082719) and HIV-1 D760(ECACC V92082720) are disclosed, which represent a further independent subtype of the HIV-1 family and have been recovered from Indian patients which at the time when the virus was isolated showed no typical AIDS symptoms. Also disclosed are vaccines against HIV-1 infections by this subtype and a process for producing the same, as well as the use of the HIV-1 infection, as well as for differential diagnosis.
Type:
Grant
Filed:
February 25, 1999
Date of Patent:
June 19, 2001
Assignee:
Chemotherapeutisches Forschungsinstitut
Inventors:
Ursula Dietrich, Hagen Von Briesen, Manuel Grez, Helga Rubsamen-Waigmann
Abstract: A mycobacteria transformed with an antigen-encoding gene, such as nef, under the control of a Streptomyces stress-responsive promoter, such as the S. albus groES/groEL1 promoter, and preferably associated with a synthetic ribosome binding site. The recombinant mycobacteria can be used as a vaccine against, for example, a pathogen which carries the antigen.
Abstract: A composition resulting from a combination of trans-dominant variants of two viral proteins TAT and REV from HIV, and the use thereof as a combination product are disclosed. A vector for expressing the two variants, a eukaryotic cell containing the same, and a pharmaceutical composition for treating viral infections, are also disclosed.
Abstract: The invention is directed to peptides of the HIV-1 envelope protein presenting multiple immune determinants. The peptide elicits both humoral and cell-mediated immune responses in mice having a variety of MHC types. In other embodiments, the invention is directed to immunogens composed of the peptides and methods for immunization employing them.
Type:
Grant
Filed:
May 31, 1995
Date of Patent:
April 10, 2001
Assignee:
The United States of America as represented by the Department
of Health and Human Services
Inventors:
Jay A. Berzofsky, Jeffrey D. Ahlers, C. David Pendleton, Peter Nara, Mutsunori Shirai
Abstract: This invention is directed toward a peptide corresponding to an immunologically important viral epitope. Specifically, the peptide corresponds to an immunodominant epitope identified in the gp120 region of the human immunodeficiency virus type 1 (HIV-1), strain Ant70. This peptide has the following amino acid sequence: NH2-Gln-Ile-Asp-Ile-Gln-Glu-Met-Arg-Ile-Gly-Pro-Met-Ala-Trp-Tyr-Ser-Met-Gly-Ile-Gly-Gly-CO2H. The invention also relates to the use of this peptide, particularly when biotinylated in the form of complexes of streptavidin-biotinylated peptides or of avidin-biotinylated peptides, for the in vitro determination of HIV-1-specific antibodies.
Abstract: A method is provided for inducing a systemic immune response to an antigen selected from inactivated HIV I and HIV II antigens in a mammal. The method comprises orally administering lyophilized multilaminar liposomes containing the antigen. The liposomes have a size of from 20 nm to 20 microns. The antigen-containing liposomes are absorbed in the Peyer's patches of the gut. Sufficient antigen-containing liposomes are taken up by macrophages in the Peyer's patches to induce a systemic immune response to the antigen.
Abstract: A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-terminal Pro). Vaccinal and pharmaceutical compositions can contain one or more such peptides associated with carrier proteins, in multiple antigenic peptides or as part of recombinant proteins. Various combinations of the Epitope I through IV peptides can provide other compositions useful in eliciting anti-Tat antibodies which cross-react with multiple strains and variants of HIV-1 Tat protein.
Abstract: The present invention provides an anti-cyanovirin antibody with an internal image of gp120, a method of using an anti-cyanovirin antibody with an internal image of gp120 to induce an immune response to gp120 so as to prevent or treat a viral infection in an animal, and a method of using a cyanovirin to induce an immune response to gp120 so as to prevent or treat a viral infection in an animal.
Type:
Grant
Filed:
August 19, 1998
Date of Patent:
February 27, 2001
Assignee:
The United States of America as represented by the Department
of Health & Human Services
Abstract: The subject invention provides new uses for novel derivatives of cyclosporine A and antibodies directed thereto. Specifically, the derivatives and antibodies are useful in methods of treating AIDS, methods of purifying the Gag protein of HIV, methods of screening for anti-HIV compounds, and methods for detecting HIV in a subject. The derivatives and antibodies can also be incorporated into a kit useful for screening for anti-HIV compounds.
Type:
Grant
Filed:
January 8, 1998
Date of Patent:
January 23, 2001
Assignee:
The Trustees of Columbia University in the City of New
York
Abstract: The present invention relates generally to chimeric peptides comprising one or more protective epitopes in a conformation enabling inmunological interactivity and to vaccine compositions comprising same. The present invention is particularly directed to a chimeric peptide capable of inducing protecting antibodies against Group A streptococci.
Type:
Grant
Filed:
July 31, 1997
Date of Patent:
January 16, 2001
Assignees:
Counsel of the Queensland Institute of Medical
Research, Commonwealth Scientific and Industrial Research
Organisation, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research of Royal
Melbourne Hospital, Biotech Australia PTY Limited, CSL Limited
Inventors:
Juan Anton Cooper, Wendy Anne Relf, Michael Francis Good, Allan James Saul
Abstract: Immunogenic compositions and methods of stimulating an immune response against the envelope protein of HIV-1. Immunogenic compositions include a purified oligomeric structure that comprises a C-terminally truncated form of HIV-1 gp160 protein that is missing the gp41 transmembrane domain. The gp120-gp41 proteolytic processing site is retained in one form of the composition and is deleted in a different form of the composition. In one embodiment, the engineered env protein is proteolytically cleaved, but the gp120 and gp41 components of the complex remain noncovalently associated. Immunization with these compositions advantageously stimulates the production of conformation-dependent antibodies.
Type:
Grant
Filed:
April 30, 1998
Date of Patent:
January 9, 2001
Assignee:
The United States of America as represented by the Department
of Health and Human Services
Inventors:
Patricia L. Earl, Christopher C. Broder, Robert W. Doms, Bernard Moss